Male, M.D, chief physician, professor, Ph.D. supervisor, director of hematology department and blood transfusion department of Beijing Tiantan Hospital. He is the deputy dean of department of hematology, capital medical university.

In 1996, he obtained his doctorate in Peking union medical college. In the same year, he began to work in hematology department of Beijing Tongren hospital, successively served as attending physician and associate chief physician, in charge of hematopoietic stem cell transplantation program. In 2000, as a visiting scholar, he went to USA to study blood oncology in Cincinnati University. From 2001 to 2006, he served as a Postdoctoral Research Fellow in the tumor gene therapy center of University of North Carolina at Chapel Hill. In 2007, he was employed as a Senior Research Associate in the University of North Carolina at Chapel Hill followed earning the physician qualification certificate in the Unite State. He Mainly engaged in hemophilia gene therapy and blood tumor targeting therapy. His research results have published in the international famous journal, such as Cancer Research, Oncogene, P.N.A.S etc which had been widely cited. In October 2011, he had been introduced to Beijing Tiantan hospital affiliated to Capital Medical University, and worked in the hematology department.

Specialty: Chemotherapy and biological target therapy of primary central nervous system lymphoma, hematopoietic stem cell transplantation, and diagnosis and treatment of leukemia etc.

Main results: 1. As the head, completed the domestic first allogeneic peripheral blood stem cell transplantation therapy for severe aplastic anemia. The patient have survived 13 years, is one of the longest survival patients. 2. To prove intramuscular AAV1 adeno-associated virus carrier effective in the treatment of hemophilia animal , which lie the foundation for clinical therapy experiment. 3. Found the key role of the cells surface receptor HER2 and ACK1 non-receptor kinase in prostate cancer, which provided important experimental basis for the research of new target therapy drugs.

4. First of all, he proved that the anti-leukemia drugs Dasatinib could effectively inhibit the growth of prostate cancer cells, contributed to extend the scope of clinical application of the drug.

Research direction: 1. Chemotherapy and biological target therapy of primary central nervous system lymphoma. 2. Comprehensive treatment and individualized treatment of blood tumors. 3. To research the meaning of auto-hematopoietic stem cell storage and transplantation in early stage.4. The impact of rheumatic autoimmune disease to the blood system.